<DOC>
	<DOCNO>NCT00311532</DOCNO>
	<brief_summary>The primary objective study estimate incidence new-onset valvulopathy , determine baseline follow-up echocardiogram , patient Parkinson 's Disease receive pergolide second-line therapy . The secondary objective study estimate prevalence valvulopathy , determine baseline echocardiogram , among patient Parkinson 's Disease consider pergolide second-line therapy .</brief_summary>
	<brief_title>Observational Study Pergolide Mesylate Cardiac Valvulopathy</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Pergolide</mesh_term>
	<criteria>Male female , age 18 old diagnosis Parkinson 's Disease Receiving pergolide secondline therapy prescribe Summary Product Characteristics Willing participate sign consent release medical information Have echocardiogram within 3 month initiation pergolide therapy evidence cardiac valvulopathy There exclusion criterion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>